Enanta 10-K: $68.2M FY26 Loss, $194.5M Cash Funds Operations Into Fiscal 2029
ENTA is trading near its 52-week low of $8.605 (4.5% above the low) on elevated volume (3.1× avg).
Summary
Enanta's fiscal 2026 10-K shows a $68.2M net loss on $63.0M of royalty revenue, with $194.5M in cash and securities projected to fund operations into fiscal 2029. The report details the post-restructuring cost base and 2027 clinical readouts for zelicapavir.
Key Events · Earnings and Guidance · ENTA
-
Fiscal 2026 Loss Narrows to $68.2M
Full-year net loss of $68.2M ($2.35 per share) on $63.0M of royalty revenue, versus an $81.9M loss on $65.3M in fiscal 2025.
-
Cash Runway Into Fiscal 2029
$194.5M in cash, cash equivalents and marketable securities at September 30, 2026, plus the retained 45.5% of HCV royalties, is projected to fund operations into fiscal 2029; no going-concern qualification.
-
Cost Base Cut, Interest Expense Up
R&D fell to $88.5M from $106.7M and G&A to $36.8M from $43.9M, while interest expense rose to $14.1M from $7.7M on higher forecast royalties owed to OMERS.
-
Zelicapavir Readouts Set for 2027
RESOLVE Phase 2b/3 dosed its first patient in October 2026 with Phase 2b topline expected in 2027; LOTUS pediatric topline is expected in the first quarter of 2027.
Analysis · ENTA · Life Sciences
The annual report puts hard numbers on a shrinking business: royalty revenue slipped to $63.0M from $65.3M as AbbVie's HCV sales erode, and the company lost $68.2M for the year. What matters is the runway — $194.5M of cash and securities plus the retained 45.5% of HCV royalties is projected to carry Enanta into fiscal 2029, so there is no near-term financing emergency even with the $75M ATM sitting unused. The cost side has already been cut hard: R&D fell to $88.5M from $106.7M and headcount is down to 74 after the September reduction of roughly one-third. The offsetting drag is interest expense, which jumped to $14.1M from $7.7M because higher forecast MAVYRET/MAVIRET royalties flow to OMERS under the 2023 royalty sale. Pipeline timing is the swing factor: zelicapavir's RESOLVE Phase 2b data land in 2027 and LOTUS pediatric topline in 1Q 2027, while the STAT6 IND has slipped to 2Q 2027 on a manufacturing delay.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $8.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $253.1M. The 52-week trading range was $8.61 to $17.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.